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SUMMARY
Myelofibrosis is a severe myeloproliferative neoplasm characterized by increased numbers of abnormal bone
marrow megakaryocytes that induce fibrosis, destroying the hematopoietic microenvironment. To determine
the cellular andmolecular basis for aberrantmegakaryopoiesis inmyelofibrosis, we performed single-cell tran-
scriptome profiling of 135,929 CD34+ lineage hematopoietic stem and progenitor cells (HSPCs), single-cell
proteomics, genomics, and functional assays. We identified a bias toward megakaryocyte differentiation
apparent from early multipotent stem cells in myelofibrosis and associated aberrant molecular signatures. A
sub-fraction of myelofibrosis megakaryocyte progenitors (MkPs) are transcriptionally similar to healthy-donor
MkPs, but the majority are disease specific, with distinct populations expressing fibrosis- and proliferation-
associated genes. Mutant-clone HSPCs have increased expression of megakaryocyte-associated genes
compared to wild-type HSPCs, and we provide early validation of G6B as a potential immunotherapy target.
Our study paves the way for selective targeting of the myelofibrosis clone and illustrates the power of single-
cell multi-omics to discover tumor-specific therapeutic targets and mediators of tissue fibrosis.
INTRODUCTION
Advances in single-cell technologies have recently provided new
insights into the cellular andmolecular diversity and pathological
mechanisms underlying many diseases, including cancers, pre-
malignant and non-malignant conditions (Baslan and Hicks,
2017; Owen et al., 2018; Parikh et al., 2019). Parallel interrogation
ofmutation status and the transcriptomeat a single-cell level pro-
vides an unprecedented opportunity to identify cancer-cell-spe-
cific targets (Giustacchini et al., 2017; Nam et al., 2019; Rodri-
guez-Meira et al., 2019). Single-cell resolution also uniquely
enables the identification of rare cell types and analysis of combi-
natorial patterns of gene expression, both ofwhich are necessary
to reconstruct differentiation trajectories and to accurately define
cellular heterogeneity between populations, such as normal and
malignant tissues, as well as to identify the mediators of
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interactions between different cell types. For example, patholog-
ical fibrosis underliesmany prevalent diseases, including cancer,
where fibrosis is well recognized to be important for disease pro-
gression and metastasis (Chandler et al., 2019; Cox and Erler,
2014). It is broadly proposed that pro-fibroticmediators secreted
by cancer cells and infiltrating immune cells activate non-malig-
nant stromal cells, such as myofibroblasts, to deposit collagen
fibrosis (Cox and Erler, 2014). However, an understanding of
the specific cellular populations that mediate fibrosis in a given
disease model, their molecular features, and the cellular path-
ways through which they are generated is necessary for these
cells to be therapeutically targeted.
Myelofibrosis is themost severeof the ‘‘myeloproliferative neo-
plasms’’ (MPNs), a group of heterogeneous disorders that result
from somatic mutations in hematopoietic stem and progenitor
cells (HSPCs) affecting Janus Kinase (JAK) signaling. The most
common driver mutation is JAK2V617F, occurring in 60% of
myelofibrosis patients (James et al., 2005), with mutations
affecting calreticulin (mutCALR) found in themajority of other pa-
tients (Klampfl et al., 2013; Nangalia et al., 2013). Myelofibrosis
can occur as a primary disorder (PMF) or develop secondary to
the other MPNs polycythemia vera (post-polycythemia vera
myelofibrosis [PPV-MF]) or essential thrombocythemia (post-
essential thrombocythaemia myelofibrosis [PET-MF]). Myelofi-
brosis is characterized by a progressive bone marrow fibrosis
that destroys the hematopoietic microenvironment, resulting in
the cardinal disease features of cytopenias, mobilization of
HSPCs to peripheral blood, extramedullary hematopoiesis, and
a high propensity for leukemia. Survival is typically 5–10 years
from diagnosis and is not substantially improved by currently
available drug therapies (O’Sullivan and Harrison, 2018). Mega-
karyocytes, the platelet-producing cells in the bone marrow,
are dramatically increased in number in myelofibrosis and are
one of the key cellular drivers of the destructive bone marrow re-
modelling by releasing excess pro-fibrotic cytokines and growth
factors (Ciurea et al., 2007; Eliades et al., 2011; Martyré et al.,
1997;Wenet al., 2015). In normal hematopoiesis,megakaryocyte
progenitors (MkPs) have a low proliferation rate, typically under-
going less than 8 cell divisions beforemitotic arrest and the onset
of polyploidization (Paulus et al., 2004), and megakaryoyctes are
relatively rare cells in healthy bone marrow.
The cellular and molecular pathways that give rise to the
dramatically increased megakaryocyte numbers and megakar-
yocyte dysfunction leading to tissue fibrosis are unclear. In tradi-
tional models of normal hematopoiesis, megakaryocytes are
said to arise from a bipotent progenitor shared with the erythroid
(red cell) lineage—the megakaryocyte-erythroid progenitor
(MEP) (Akashi et al., 2000; Debili et al., 1996; Kondo et al.,
1997; Manz et al., 2002; Pang et al., 2005; Psaila et al., 2016;
Psaila and Mead, 2019; Sanada et al., 2016). Recent advances
in single-cell technologies, including single-cell transplantation
and lineage tracing studies of unperturbed hematopoiesis,
have revealed that hematopoiesis occurs over a continuum
rather than by distinct, oligopotent intermediate steps (Laurenti
and Göttgens, 2018; Psaila and Mead, 2019; Velten et al.,
2017) and also that a proportion of hematopoietic stem cells
(HSCs), at least in themurine system, aremegakaryocyte-biased
but retain the capacity for multilineage reconstitution (Adolfsson
et al., 2005; Benz et al., 2012; Carrelha et al., 2018; Rodriguez-
Fraticelli et al., 2018; Sanjuan-Pla et al., 2013; Shin et al.,
2014). Lineage-committed megakaryocytes arising directly
from HSCs, sometimes without cell division, have also been re-
ported (Notta et al., 2016; Roch et al., 2015).
Targetingmegakaryocytes inmyelofibrosis has been shown to
ameliorate the disease in mousemodels and early-phase human
studies (Eliades et al., 2011; Wen et al., 2015), but technical chal-
lenges have precluded the extensive study of megakaryopoiesis
in myelofibrosis patients. These challenges include the rarity of
megakaryocytes in healthy bonemarrow, gaps in our knowledge
of the cellular pathways of megakaryopoiesis, and their extreme
cell size and fragility. In addition, the severe fibrosis typically pre-
vents bone marrow aspiration (‘‘dry tap’’ aspirate). However,
bone marrow HSPCs are mobilized to the peripheral blood in
myelofibrosis. In this study, we used this phenomenon to capture
peripheral blood HSPCs and perform the first in-depth single-
cell analysis of abnormal megakaryocyte differentiation and
function in patients with myelofibrosis, suggesting key cellular
and molecular targets. Using multiparameter immunophenotyp-
ing, functional studies, high-throughput single-cell RNA
sequencing (scRNA-seq), targeted single-cell mutational anal-
ysis with simultaneous scRNA-seq (TARGET-seq) (Rodriguez-
Meira et al., 2019), and single-cell proteomics, we identify
potential targets for the inhibition of pathological megakaryocyte
differentiation and megakaryocyte-induced fibrosis and validate
G6B as a cell surfacemarker that may enable specific ablation of
myelofibrosis cells using immunotherapy. This study illustrates
the power of single-cell ‘‘multi-omics’’ in the characterization
of cellular heterogeneity in cancers associated with aberrant
fibrosis, including the identification of potential therapeutic path-
ways and cancer-cell-specific targets.
RESULTS
Analysis of Mobilized HSPCs Demonstrates
Megakaryocyte-Biased HSCs in Myelofibrosis
Multi-parameter flow cytometric analysis of the CD34+ lineage
(lin) HSPC compartment in peripheral blood samples from
healthy mobilized apheresis donors and patients with myelofi-
brosis (Table S1) was performed to compare frequencies of the
classically defined HSPC subsets (Figure 1A). This demon-
strated reduced lymphoid-primed multipotent progenitors
(LMPPs) and increased multi-potent progenitors (MPPs; Fig-
ure 1A) in myelofibrosis patients. The cell-surface antigen
CD41 has previously been reported to identify cells primed for
megakaryocyte differentiation (Gekas and Graf, 2013; Haas
et al., 2015; Psaila et al., 2016; Yamamoto et al., 2013). A
5-fold increase in the percentage of CD41+ cells was detected
within both CD38-negative, early stem/progenitor (HSC and
MPP) and CD38-positive, down-stream progenitor (MEP and
common myeloid progenitor [CMP]) cell fractions (Figures 1A
and 1B), suggesting a bias towardmegakaryocyte differentiation
originating during the earliest phases of HSC lineage
commitment. Morphological analysis of CD38CD41+ and
CD38+CD41+ cells from the CD34+linCD45RA compartment
showed undifferentiated blast cell morphology and not mature
megakaryocytes (Figure S1A).
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The CD41+ fraction of human CD38-positive CD34+ lin
CD45RA HSPCs contains megakaryocyte-biased progenitors
with significant erythroid differentiation potential as well as uni-
potent MkP (Miyawaki et al., 2017; Psaila et al., 2016). However,
the phenotype of CD41+ cells within the CD38-negative HSC/
MPP compartment has not previously been defined. We, there-
fore, sought to determine whether the CD41+ HSCs and MPP
cells isolated from healthy donors retained a capacity for multi-
lineage differentiation or were lineage-committed MkP. CD34+
Lin– CD38– CD45RA– CD90+ CD41– (CD41– HSC), CD34+ Lin–
CD38– CD45RA– CD90– CD41– (CD41–MPP), and CD34+Lin–
CD38– CD45RA–CD41+ (CD41+HSC/MPP) cells were isolated
by fluorescence-activated cell sorting (FACS) for liquid culture
differentiation assays. When stimulated with thrombopoietic cy-
tokines, CD41+ HSC/MPP cells showed accelerated megakar-
yocyte differentiation with a substantially higher proportion of
A
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Figure 1. Multipotent Myelofibrosis He-
matopoietic Stem and Progenitor Cells
(HSPCs) Are Biased for Megakaryocyte
Differentiation
(A) Left: model of classically defined CD34+ lin
HSPC subpopulations, in which multi-potent cells
(HSCs, hematopoietic stem cells; MPPs, multi-
potent progenitor cells; LMPPs, lymphoid-primed
multi-potent progenitors) are CD38 and down-
stream progenitors (CMPs, common myeloid
progenitors; MEPs, megakaryocyte-erythroid pro-
genitors; GMPs, granulocyte-monocyte pro-
genitors) are CD38+. CD45RA+ populations (LMPP/
GMP) do not have erythroid or megakaryocyte po-
tential. Middle: % of each classically defined HSPC
population in the CD34+ lin compartment,
demonstrating increased MPPs and reduced
LMPPs inmyelofibrosis (MF) compared to controls.
Right: % cells expressing CD41, a surface antigen
previously shown to identify cells with increased
potential for megakaryocyte differentiation, is
increased inbothCD38CD45RA (HSC/MPP)and
CD38+ CD45RA (CMP/MEP) compartments in
myelofibrosis (MF patients, N = 23; controls, N = 14,
see also Table S1).
(B) Representative FACS plot of a healthy donor
control and myelofibrosis patient showing gating
strategies.
(C) Left: FACS analysis of CD41 HSC (top),
CD41 MPP (middle), and CD41+ HSC/MPP
(bottom) from healthy donors cultured in mega-
karyocyte differentiation media (with added re-
combinant human TPO and stem cell factor
[SCF]). CD41+ HSC/MPP demonstrate increased
potential for megakaryocyte differentiation, with
faster acquisition of the mature megakaryocyte
antigen CD42 at an early time point (day 6). Right:
images of cultures showing enlarged cell size and
proplatelet formation (red star) indicative of
accelerated megakaryocyte differentiation from
CD41+ HSC/MPP. Representative examples of 3
replicate experiments shown.
(D) FACS analysis of CD41 HSC, CD41 MPP
and CD41+ HSC/MPP from healthy donors
cultured for 12–14 days in megakaryocyte (MK),
erythroid (Ery), or myeloid (Mye) differentiation
media. CD41+ HSC/MPP showed a higher % of
mature CD41+42+ megakaryocytes and glyco-
phorin A+ CD71+ erythroblasts and equivalent
CD11b/CD14+ myeloid cells versus CD41 frac-
tions. Representative examples of 3 replicate ex-
periments shown. % of total live (7AAD-), single
cells shown.
(E) Summary chart (left) and representative FACS plots (right) showing percentage of myelofibrosis and control CD41 HSC/MPP cultured in ‘‘bi-potent’’
erythroid and megakaryocyte differentiation media that give rise to megakaryocyte versus erythroid progeny 6 days after plating (gated on live cells). (controls,
n = 7; myelofibrosis [MF], n = 8). Charts show mean + SEM,***p < 0.001; **p % 0.01; *p < 0.05). See also Figure S1.
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cells expressing the mature megakaryocyte surface antigen
CD42, a large cell size, and proplatelet extensions at early time
points as compared to CD41– HSCs and MPPs (Figure 1C). In
parallel megakaryocyte, erythroid, and myeloid differentiation
assays, CD41+ HSC/MPP showed a similar potential for
CD11b/CD14+ myeloid differentiation and a superior potential
for CD71+/glycophorin A erythroid differentiation than CD41–
fractions (Figure 1D).
In comparison to those from healthy donors, CD41–HSC/MPP
cells from myelofibrosis patients showed a megakaryocyte
versus erythroid differentiation bias (Figure 1E), in keeping with
the clinical phenotype of myelofibrosis patients in which exces-
sive megakaryocyte numbers occur in parallel with anemia. In
single-cell clonogenic assays supportive of myeloid and
erythroid (but not megakaryocytic) colony formation (methocult),
CD41+ and CD41– fractions of HSCs and MPPs gave rise to ex-
pected colony frequencies with myelofibrosis CD41- HSC/MPP
showing a bias toward myeloid versus erythroid colonies (Fig-
ure S1B). Together, these results support that in myelofibrosis,
HSPCs are biased towardmegakaryocyte-lineage differentiation
from the earliest stem cell compartment, even before expression
of canonical megakaryocytic markers.
High-Throughput scRNA-Seq Identifies a Distinct
Pathway for Megakaryocyte Differentiation in
Myelofibrosis
To identify the cellular and molecular basis for megakaryocyte-
biased hematopoiesis in myelofibrosis without bias from pre-
selected cell surface antigens, high-throughput scRNA-seq
was performed on 135,929 individual CD34+ lin–HSPCs from pa-
tients with JAK2V617F+ or mutCALR+ myelofibrosis (93,157
cells, n = 15) according to World Health Organization (WHO)
criteria (Arber et al., 2016) and age-matched healthy donors
(42,772 cells, n = 6) by using the 10x Genomics Chromium plat-
form (Table S2). Filtering, quality control and doublet exclusion
was performed (Table S3). Healthy donor control and myelofi-
brosis cells were aggregated and individual donor effect was
regressed out, following which no batch effect remained (Fig-
ure S1C). A contaminating population of plasmacytic dendritic
cells was identified and removed from all down-stream analysis
(Figure S1D). Following these steps, 120,196 cells (82,255
myelofibrosis and 37,941 control cells) were used for down-
stream analyses (Table S3).
Dimensionality reduction and unsupervised clustering were
performed using a uniform manifold approximation and projec-
tion (UMAP) method combined with the Louvain community-
detection clustering method to enable identification of distinct
cell populations while preserving inter-cluster relationships
(Becht et al., 2018) (Figure 2A). A total of 8 clusters were identi-
fied and manually annotated by correlation of differentially ex-
pressed genes for each cluster with reference marker genes
for each lineage (Buenrostro et al., 2018; Hua et al., 2019; Pellin
et al., 2019; Popescu et al., 2019) (Figure 2A; Figure S1E;
Table S4). ‘‘Lineage signature’’ gene sets were established by
an analysis of published datasets (Buenrostro et al., 2018; Hua
et al., 2019; Pellin et al., 2019; Popescu et al., 2019) to identify
genes selectively expressed in erythroid, myeloid, lymphoid,
and megakaryocyte lineage progenitors and uncommitted
A
C D
B Figure 2. High-Throughput Single-Cell RNA
Sequencing of 120,196 CD34+ lin– HSPCs
from 21 Donors Reveals Marked Expansion
of Megakaryocyte Progenitors (MkPs) in
Myelofibrosis
(A) Dimensionality reduction using UMAP of an
aggregate of all control (n = 37,941) and myelofi-
brosis (n = 82,255) cells identified 8 distinct clus-
ters. Cells were partitioned using the Louvain
community-detection clustering method and an-
notated according to expression of lineage
signature genes for hematopoietic cell types (see
also Table S4). Abbreviations: Ery - erythroid;
Mye - myeloid; Lymph -lymphoid progenitor.
(B) Expression of lineage signature gene sets were
superimposed on the UMAP (gray, uncommitted
or expression of >1 lineage gene set; see also
Table S5).
(C) Cells were colored according to the donor type
(healthy donors, blue; myelofibrosis, red).
(D) Myelofibrosis cells were down-sampled to
match the number of control cells (37,941 cells).
Bar chart shows the % of cells within each anno-
tated lineage progenitor cluster deriving from each
donor type. N = 15 for myelofibrosis patients
(3 mutCALR+ and 12 JAK2V617F+) and N = 6 for
age-matched controls. See also Figure S1F and
Tables S2 and S3.
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HSPCs and were superimposed on the UMAPs (Figure 2B; Fig-
ures S1F and S2; Table S5).
Most HSPCs expressing megakaryocyte signature genes were
derived frommyelofibrosis patients with very few fromhealthy do-
nors (Figures 2B–2D; Figure S1F). The average proportion of
HSPCs with a megakaryocyte gene signature was 5% for indi-
vidual myelofibrosis patients, 11-fold higher than for healthy do-
nors (4.98% [range, 0.52%–19.81%] for myelofibrosis versus
0.44% [range, 0%–1.51%] for controls, p < 0.05). Down-sampling
the myelofibrosis cells to create a dataset with equal numbers of
control and myelofibrosis HSPCs confirmed that over 93% of
HSPCs in the MkP cluster originated from myelofibrosis donors,
whereas less than 10% lymphoid progenitor cells were from
myelofibrosis patients. The fractions ofmyeloid and erythroid pro-
genitor cells were not significantly different (Figures 2D and S1F),
supporting a strong megakaryocyte bias and reduction in
lymphoid differentiation in myelofibrosis.
To study differentiation trajectories, cells were ordered in gene
expression space by using force-directed graphs (FDG), and the
lineage signature gene scores were superimposed on the graphs
(Figures 3A–3D). The HSPC signature highlighted cells at the
origin of the trajectory, and erythroid, megakaryocyte, myeloid,
and lymphoid trajectories formed distinct paths, with MPP cells
primarily located in intermediate positions in the trajectories
(gray cells, Figures 3A–3D, left plots; Figure S3). Expression of
megakaryocyte signature genes (purple) was observed along a
prominent distinct trajectory originating from the apex of the
HSPC cluster in the FDG trajectory in myelofibrosis patients (Fig-
ures 3B and 3D). In contrast, in healthy donors, very few MkP
cells were observed in a distinct differentiation trajectory (Fig-
ures 3C and 3D). Notably, most of these cells derived from two
of the six healthy donors (donors ID06 and ID09; Figure S3C).
Together with functional data (Figure 1), these data support a
model in which a direct route for MkP production from HSPCs
is aberrantly expanded in JAK2V617F and mutCALR-driven
myelofibrosis. Our observations were consistent across all clin-
ical and molecular patient subgroups (Figures S3A–S3C), and
trajectory analyses using diffusion maps created with Scanpy,
an alternative toolkit (Wolf et al., 2018), confirmed findings with
our in-house analysis pipeline (Figure S3D).
Identifying Molecular Drivers for Aberrant
Megakaryopoiesis in Myelofibrosis
We next sought to identify molecular regulators that might spe-
cifically drive aberrant megakaryocyte differentiation in myelofi-
brosis and may potentially be targeted without major toxicity to
the other blood cell lineages. Trajectory analysis of all myelofi-
brosis HSPCs performed using the Scanpy toolkit (Wolf et al.,
2018) demonstrated a distinct trajectory for megakaryocyte dif-
ferentiation through ‘‘pseudotime’’ from an HSC origin (HSC /
HSPC2 / Mega; Figure 4A). Expression patterns of 1,639 hu-
man transcription factors (Lambert et al., 2018) were analyzed,
and transcription factors showing progressive changes over
the megakaryocyte and erythroid differentiation trajectories,
either increased or decreased expression, were identified. Ex-
pected differential expression patterns of transcription factors
known to be involved in megakaryocyte versus erythroid lineage
specification were observed, e.g., progressive increase in
GATA1 and GATA2 and antagonistic expression of two key reg-
ulators of megakaryocyte-erythroid cell fate decision, namely
FLI1 and KLF1 (Bouilloux et al., 2008; Doré and Crispino, 2011;
Frontelo et al., 2007; Palii et al., 2019; Siripin et al., 2015) (Figures
4B and 4C). Additional genes not previously implicated as regu-
lators of megakaryocyte versus erythroid differentiation showed
striking differential expression between the erythroid and mega-
karyocyte trajectories, including YBX1, HMGA1, PLEK, SOX4,
and MYC (Figures 4B and 4C), suggesting additional targets
for strategies to specifically inhibit pathological megakaryopoie-
sis while preserving erythropoiesis in myelofibrosis patients.
Identifying Mediators of Megakaryocyte-Induced
Fibrosis
To evaluate the pathological role of the expanded MkPs in
driving bone marrow fibrosis, we next examined potential medi-
ators of fibrosis among HSPCs. Fibrosis regulators were identi-
fied from previously published datasets studying lung and liver
fibrosis as well as bonemarrow fibrosis (Allen et al., 2017; Black-
man et al., 2013; Corvol et al., 2015; Gu et al., 2009; Mondet
et al., 2015; Mushiroda et al., 2008; Noth et al., 2013; Ulveling
et al., 2016; Wattacheril et al., 2017; Wright et al., 2011). Genes
detected at expression levels over 1 (using log-transformed
unique molecular identifier [UMI]) in our HSPC dataset were
selected for a ‘‘fibrosis signature’’ gene score (Table S5). Super-
imposition of this score on the UMAP for all healthy donor and
myelofibrosis HSPCs clearly highlighted the MkP cluster cells
as being the key regulators of fibrosis among all HSPCs
(Figure 5A).
Healthy donor andmyelofibrosisMkPswere then extracted for
further analyses (Figure S4A). Gene set enrichment analysis
(GSEA) of all expressed genes pre-ranked according to their dif-
ferential expression between myelofibrosis and control MkP
showed significant enrichment of metabolic (e.g., oxidative
phosphorylation and fatty acid metabolism) and inflammatory
pathways (e.g., transforming growth factor a [TNF-a] signaling
and interferon gamma response) in myelofibrosis MkPs (Fig-
ure 5B). A subset of myelofibrosis MkPs (cluster cluster 6)
showed a similar gene expression profile to control MkPs (Fig-
ures 5C and 5D). These cells had a high expression of key inflam-
matory mediators previously implicated in myelofibrosis,
including PDGFA, CCL5, and CXCL5 (Figures 5C and 5D) (Eli-
ades et al., 2011; Malara et al., 2018; Mascarenhas et al.,
2017). However, themajority of myelofibrosisMkPs had a unique
gene expression profile with overall upregulation of genes nor-
mally expressed at low levels in healthy donor MkPs (Figures
5C and S4B). This finding suggests that megakaryocyte-induced
fibrosis in myelofibrosis is due to both expansion of a population
of megakaryocytes analogous to those in normal bone marrow
as well as the generation of an aberrant population, an observa-
tion that would not have been possible without analysis at the
single-cell resolution.
Myelofibrosis MkPs Demonstrate Molecular
Heterogeneity with Differential Expression of
Proliferation and Fibrosis Genes
To further dissect cellular and molecular heterogeneity among
myelofibrosis MkP, unsupervised clustering using Louvain
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community detection was performed on myelofibrosis MkP.
Nine sub-clusters were identified with distinct expression of
fibrosis and proliferation-associated genes (Figures 5D, 5E,
and S5A). Genes encoding key mediators of fibrosis (TGFB1,
TNF, and LTBP1, which encodes a protein that targets the latent
form of transforming growth factor beta [TGF-b] and contributes
to its activation; Robertson et al., 2015), were most highly ex-
pressed in MkP clusters 6–8, whereas MkP clusters 2 and 8
A
B
C
D
Figure 3. A Distinct Trajectory for Megakaryocyte Differentiation Is Dramatically Expanded in Myelofibrosis
(A–D) Force-directed graphs (FDGs) for aggregate of all control + myelofibrosis cells (A), myelofibrosis only (B), control only (C), and control + down-sampled
myelofibrosis dataset (D). In (D), the left graph shows lineage signature gene score and in the right graph cells are colored according to the donor type (healthy
donors, blue; myelofibrosis, red). Gene expression trajectories are visualized by superimposing the expression scores of lineage signature gene sets on FDG.
Grey cells represent uncommitted HSPCs or cells with expression of more than 1 lineage signature. See also Figures S2 and S3 and Table S5.
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showed the highest expression of the proliferation markerMKI67
and a G2M gene signature (Figures 5E and S5B). AURKA was
selectively expressed in two clusters, with particularly high
expression in the minor cluster 8 (Figure 5E). This is of interest
as AURKA is the target for alisertib (MLN8237), which was
recently demonstrated to promote megakaryocyte polyploidiza-
tion and ameliorate the myelofibrosis phenotype in mouse
models (Wen et al., 2015), with some efficacy also in patients
with myelofibrosis (Gangat et al., 2019).
A
B
C
Figure 4. Molecular Regulators That May
Drive Aberrant Megakaryocyte Differentia-
tion in Myelofibrosis
(A) Left: FDG generated using Scanpy of all
myelofibrosis CD34+ lin cells, showing unsuper-
vised clusters based on Louvain community-
detection method. Right: pseudotime for the dif-
ferentiation path from HSCs superimposed on the
FDG plot.
(B) Expression of selected transcription factor
genes over pseudotime from HSC / HSPC2 /
megakaryocyte and HSC / HSPC2 / Ery dif-
ferentiation paths.
(C) Expression of 6 genes that are differentially
expressed between the erythroid and megakar-
yocyte trajectories over pseudotime.
Normal megakaryocytes have a low
proliferation index, and healthy donor
MkPs showed low expression of the pro-
liferation marker MKI67. By contrast,
MKI67was strongly expressed in the ma-
jority of myelofibrosis MkPs and the MkP
cluster showed the highest expression of
MKI67 among all myelofibrosis HSPC
clusters (Figure S5C) as well as an enrich-
ment of a G2M checkpoint gene signa-
ture (Figure S5B; Table S5), suggesting
that increased proliferation of MkPs may
contribute to the pathological accumula-
tion of megakaryocytes in myelofibrosis,
in addition to megakaryocyte-biased
hematopoiesis.
Identifying Myelofibrosis Clone-
Specific Cell Surface Targets
Increased expression of megakaryocyte
genes in the myelofibrosis aggregate
was noted not just within the MkP cluster
but also within clusters of uncommitted
HSPCs and other lineage-affiliated clus-
ters (Figure 6A). This included intracellular
proteins (PF4 and VWF) and also cell sur-
face antigens (ITGA2B [CD41] and
MPIG6B [G6B]). Increased expression of
MPIG6B, encoding the G6B protein,
was particularly striking (Figure 6A). G6B
is an immunoreceptor tyrosine-based in-
hibition motif (ITIM)-containing inhibitory
receptor, considered to be exclusively expressed on mature
megakaryocytes in normal hematopoiesis (Coxon et al., 2017;
Senis et al., 2007). As the majority of healthy donor CD34+ lin–
HSPCs did not express megakaryocyte genes and because
mature megakaryocytes normally lose expression of CD34 dur-
ing differentiation (Tomer, 2004), we hypothesized that aberrant
co-expression of stem and progenitor and megakaryocyte sur-
face antigens may enable the selective identification of myelofi-
brosis clone-derived HSPCs.
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Patients with myelofibrosis have distinct genetic subclones
of HSPCs, including residual wild-type clones (non-mutated)
as well as clones with co-mutations in addition to driver muta-
tions (JAK2V617F or mutCALR). To determine whether the in-
crease in the expression of megakaryocyte-associated genes
was specific to mutant clone-derived HSPCs or due to cell-
extrinsic signals affecting both mutated and un-mutated
HSPCs, data generated by combined high-sensitivity muta-
tional analysis and parallel transcriptome profiling (TARGET-
seq; Rodriguez-Meira et al., 2019) were analyzed. A total of
2,734 cells were examined—678 healthy donor cells plus
2,056 myelofibrosis cells (388 JAK2 wild type and 1,668
JAK2V617F mutated). Expression of megakaryocyte genes,
in particular G6B, was significantly higher in JAK2V617F-
mutated HSPCs than in either wild-type cells from the same
patients or in wild-type cells from healthy donors (32% versus
22.9% versus 14.7%, respectively; p < 0.001; Figure 6B). Wild-
type cells from myelofibrosis patients also showed increased
frequency of G6B expression, albeit to a lower degree than
JAK2V617F-positive cells, in keeping with cell-extrinsic signals
also contributing to this aberrant megakaryocyte differentia-
tion (Figure 6B).
]The high-throughput TARGET-seq and 10x Chromium data-
sets included all CD34+ lin– cells. Expression levels of G6B were
also increased specifically in individual JAK2 mutant CD38– early
stem and progenitor cells (HSC/MPP; Figure 6C) identified from
the index sorting data of the TARGET-seq cells, and in 100-cell
‘‘mini-bulk’’ preparations of FACS-isolated immunophenotypic
CD34+ lin– CD38–CD45RA– CD90+ HSCs, CD34+ lin–CD38–
CD45RA–CD90– MPPs, and CD41+ HSC/MPPs (Figure 6D).
To examine where cells with specific genotypes fell on the
HSPC trajectory, the datasets of myelofibrosis HSPCs analyzed
by high-throughput 10x Genomics and TARGET-seq were inte-
grated using Harmony (Korsunsky et al., 2019) (Figure S6A).
FDG trajectory analysis showed that both wild-type and mutant
progenitors fell in all 3 of the lineage progenitor trajectories
(myeloid, erythroid, and megakaryocyte; Figure S6A). However,
a higher proportion of the cells in the megakaryocyte and myeloid
trajectoriesweremutant versuswild type than the erythroid trajec-
tory (FigureS6A, right plot). In twopatientswith 3+co-mutations in
addition to the driver JAK2V617F mutation, the increase in G6B
was observed in all genetic sub-clones detected (Figure S6B).
Expression of the Cell Surface G6B Protein Selectively
Identifies Mutant Clone-Derived HSPCs in Myelofibrosis
High-throughput, single-cell proteomics by mass cytometry
time of flight (CyTOF) was performed to simultaneously mea-
sure 20 surface proteins in multiple samples in parallel by us-
ing barcode multiplexing (Figure 7A; Table S7). G6B was
consistently detected at substantially higher levels in patients
with primary and secondary myelofibrosis and with
JAK2V617F and mutCALR driver mutations than in healthy do-
nors (Figures 7A and 7B). In addition, high cell surface G6B
expression was also detected exclusively on JAK2V617F-
mutated MPN cell lines (HEL and SET2) and not on the other
leukemia cell lines, namely K562, HL60, JURKAT, and MAR-
IMO, and HEK (human embryonic kidney) cells (Figure S7A).
G6B expression was noted in both the CD41-positive and
-negative cell fractions in myelofibrosis by FACS (Figure 7B,
right plots).
To examine G6B expression in bone marrow megakaryocytes
in situ, immunohistochemical staining was performed on
trephine biopsy sections from healthy donors and patients with
mutCALR and JAK2V617F+ myelofibrosis, confirming the ex-
pected expression on control megakaryocytes but with a dra-
matic increase in G6B+ cells in myelofibrosis (Figure 7C).
To confirm G6B as a potential marker of HSPCs derived from
the malignant clone, G6B-positive and -negative cells were
FACS-isolated from healthy donor and myelofibrosis patient
MNCs and the expression of mutant versus wild-type JAK2
was determined by quantitative real-time PCR (Moliterno
et al., 2006). Expression of mutant JAK2V617F relative to
wild-type JAK2 was dramatically higher in G6B-positive cells
(Figure 7D).
To validate that aberrant co-expression of G6B by mutant
clone-derived HSPCs may be a potential strategy for immuno-
therapy, a tool bi-specific antibody was generated to target a
stem and progenitor surface antigen (CD34) and G6B and
labeled with a pH-sensitive cyanine CypHer5E dye that maxi-
mally fluoresces at an acidic pH following cellular internaliza-
tion. Rapid internalization of the bi-specific by SET-2 cells
(a JAK2V617F+ MPN cell line expressing both CD34 and
G6B), as indicated by clear intracellular fluorescence, was
observed (Figure 7E). Internalization was significantly reduced
by two inhibitors of endocytosis, Dynasore (a GTPase inhibitor
of dynamin) and Pitstop 2 (an inhibitor of the clathrin terminal
domain). Internalization was also observed in CD34-negative,
G6B+ HEL cells (Figure 7B) and not in G6B-negative cells
nor with an isotype-control antibody, confirming that internal-
ization was mediated by the G6B receptor. This strategy
may have the potential to deliver therapeutic antibody conju-
gates directly to G6B+ mutant clone-derived cells. Together,
these data identify G6B as a promising cell surface antigen
worthy of further validation as enabling selective targeting of
Figure 5. Myelofibrosis MkPs Strongly Express Mediators of Tissue Fibrosis
(A) Expression of a 14-gene ‘‘fibrosis score’’ (Table S5) derived from previously published datasets examining bonemarrow, liver, and lung fibrosis superimposed
on the UMAP of all HSPCs identifies cells in the MkP cluster as the strongest expressers of mediators of tissue fibrosis.
(B) HALLMARK pathways from gene set enrichment analysis (GSEA) of all genes pre-ranked according to differential expression in myelofibrosis versus healthy
donor MkP. Pathways with a false discovery rate (FDR) q-value of <0.25 are shown.
(C) Heatmap showing 10 selected genes differentially expressed between myelofibrosis and control MkP.
(D) Left: 9 distinct clusters of myelofibrosis MkP shown on UMAP. Right: expression of signature genes detected in healthy donor MkP and shown in (C) (ITGB5,
CCL5, CXCL5, TNFSF4, and PDGFA) shown on UMAP of myelofibrosis MkP indicates that sub-cluster 6 is transcriptionally similar to control MkP.
(E) Heterogenous expression of markers of proliferation (MKI67), fibrosis (TGFB1 and LTBP1), inflammation (TNF), and treatment targets (AURKA and AURKB)
among myelofibrosis MkP sub-clusters. Blue dots on violin plot indicate mean level of expression. See also Figures S4 and S5.
ll
Article
Molecular Cell 78, 477–492, May 7, 2020 485
A
B
C
D
Figure 6. Increased Expression of Megakaryocyte-Associated Genes in Myelofibrosis Is Not Restricted to the MF-MkP Cluster but Is Sub-
stantially Higher in Cells Derived from the JAK2V617F+ Mutant Clone
(A) Expression of intracellular (PF4 and VWF) and cell surface (ITGA2B [CD41] and G6B) megakaryocyte genes is not limited to myelofibrosis MkPs, particularly
for G6B.
(legend continued on next page)
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aberrant megakaryocytic differentiation and mutant clone-
derived HSPCs in myelofibrosis.
DISCUSSION
Bone marrow transplant is currently the only potentially curative
treatment for myelofibrosis but is associated with significant
risk and most patients are ineligible due to age and comorbid-
ities. The introduction of JAK inhibitors has led to significant
improvement in symptomatic management, but most patients
continue to experience substantial morbidity and a significant
reduction in life expectancy. New approaches to treatment
are urgently required. Megakaryocytes are well recognized as
the key cellular drivers of disease pathogenesis (Malara et al.,
2018); however, only one megakaryocyte-targeting therapy—
alisertib, a specific inhibitor of aurora kinase—has been devel-
oped to date (Gangat et al., 2019; Wen et al., 2015). A major
obstacle to identification of novel targets has been the inability
to isolate megakaryocytes from patients for detailed study. In
the present study, we reasoned that aberrant megakaryopoie-
sis in myelofibrosis is very likely to be caused by aberrant
differentiation of HSPCs, rather than proliferation of mature
megakaryocytes alone, and that this process might be
amenable to therapeutic targeting to ‘‘turn off the supply.’’
We, therefore, set out to characterize the distinct cellular and
molecular features of megakaryocyte differentiation pathways
in myelofibrosis by using a combination of single-cell ap-
proaches. We demonstrate a dramatic expansion of megakar-
yocyte differentiation from uncommitted stem and progenitor
cells in JAK2V617F-driven hematopoiesis. Furthermore, we
identify a number of molecular targets that may inhibit the
abnormal megakaryocyte differentiation and potentially ablate
mutant clone-derived HSPCs and MkPs.
Importantly, several key observations were only possible due
to the single-cell-level resolution of study, highlighting the po-
wer of single-cell technologies in understanding disease pa-
thology and in novel therapeutic target discovery. First, our
data indicate that aberrant megakaryopoiesis in myelofibrosis
is due to both a dramatic expansion of MkP with a similar
transcriptional signature to healthy donor MkPs, as well as gen-
eration of a unique, aberrant MkP population. Second, by
simultaneously interrogating the mutational status and the tran-
scriptome of individual cells, we demonstrated that certain
megakaryocyte surface antigens, in particular G6B, are mark-
edly over-expressed in mutant clone-derived HSPCs compared
with wild-type HSPCs from myelofibrosis patients or healthy
donor HSPCs. This validates combinatorial targeting of stem
cell (e.g., CD34) and megakaryocyte (e.g., G6B) surface anti-
gens, e.g., with bi-specific antibody therapies as a potential
strategy worthy of further investigation for selective ablation
of the myelofibrosis clone. As none of the currently available
treatments for MPNs reliably induce clonal remissions or
substantially reduce fibrosis, this work sets the stage for immu-
notherapeutic targeting of aberrant hematopoiesis in myelofi-
brosis. Furthermore, the approach we have adopted and the
resulting insights are highly relevant to other studies seeking
to identify cancer-cell-specific drug targets and cancer-associ-
ated fibrosis in other malignancies, as well as non-malignant
disorders of tissue fibrosis.
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Detailed methods are provided in the online version of this paper
and include the following:
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B CD34 x G6B bispecific antibody generation
B Antibody internalization experiments
B 10x Genomics single-cell RNA sequencing data pre-
processing and integration
B Dimensionality reduction, removal of individual donor
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(B and C) Simultaneous targeted mutational profiling and RNA sequencing (TARGET-seq) of 2,734 individual CD34+ Lin HSPCs (B) and CD38-negative stem
cells (C) identified by index sorting data show higher expression of megakaryocyte-associated genes ITGA2B (CD41), VWF, SELP, and G6B in JAK2V617F-
mutated (JAK2+) versus wild-type cells from the same patients (WT-pt) or age-matched healthy donor control HSPCs (WT-HD). Fraction and % of cells in which
gene expression were detected and are shown. The combined p value for Fisher’s exact test and Wilcoxon rank-sum test is shown (*p < 0.05, **p % 0.01,
***p % 0.001). Points represent expression values for each single cell, and boxes represent median and quartiles for each group.
(D) G6B expression in bulk-sorted control and myelofibrosis immunophenotypic HSC (CD34+ lin CD38CD45RACD90+), MPP (CD34+ lin
CD38CD45RACD90), and CD41+ HSC/MPP (CD34+ lin CD38-CD45RA CD41+).TPM, transcripts per million. Chart shows mean ± SEM, n = 4 for controls
and n = 3 for myelofibrosis; *p < 0.05; **p % 0.01. See also Figure S6.
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Figure 7. Expression of Cell Surface G6B, a Cell Surface Protein, Identifies Mutant Clone-Derived HSPCs in Myelofibrosis
(A) Left: expression of 6 megakaryocyte markers from a panel of 20 HSPC and megakaryocyte cell surface antigens assayed by mass spectrometry time of flight
(CyTOF) shows expression of G6B on CD34+ HSPCs from patients with primary myelofibrosis (PMF), post-essential thrombocythemia myelofibrosis (PET-MF),
and post-polycythaemia vera myelofibrosis (PPV-MF) with either JAK2V617F (JAK2+) or calreticulin (mutCALR) driver mutations. Histograms show cell count (y
(legend continued on next page)
ll
Article
488 Molecular Cell 78, 477–492, May 7, 2020
B Differentiation trajectory analysis
B Identifying patters of expression of transcription factor
genes along megakaryocyte and erythroid trajectories
in myelofibrosis patients
B GeneSet Enrichment Analysis
B Integration of 10x Genomics and TARGET-seq da-
tasets
d QUANTIFICATION AND STATISTICAL ANALYSIS
B Flow cytometry and CyTOF data analysis
d DATA AND CODE AVAILABILITY
SUPPLEMENTAL INFORMATION
Supplemental Information can be found online at https://doi.org/10.1016/j.
molcel.2020.04.008.
ACKNOWLEDGMENTS
We thank all the patients who kindly donated samples; Dr. Sally-Ann Clark and
others in the MRC WIMM Flow Cytometry facility; Dr. Michalina Mazurczyk in
the Mass Spectrometry Facility and Dr. Neil Ashley in the MRC WIMM Single
Cell Facility; Dr. Alice Young in the NIH Intramural Sequencing Center; the
NHGRI Flow Cytometry facility; the University of York Imaging and Cytometry
facility; and the National Institute for Health Research (NIHR) Oxford Biomed-
ical Research Centre (BRC). This work was funded by a Cancer Research UK
Advanced Clinician Scientist Fellowship and CRUK Innovation Award; a Well-
come Career Development Fellowship; an Academy of Medical Sciences
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CyTOF antibody cocktail This paper See Table S7
Biological Samples
Peripheral blood from patients with
myelofibrosis (see Tables S1 and S2)
INForMeD Study (IRAS 199833; REC
16/LO/1376 University of Oxford) Or
Hammersmith Hospital Imperial College
NHS Trust (R13077; 12275; REC
12/WA/0196)
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ID12,ID14,ID15,ID16,ID19,ID20,ID21
Peripheral blood from healthy mobilized
apheresis donors (see Tables 1 and 2)
INForMeD Study (IRAS 199833; REC
16/LO/1376 University of Oxford) Or
Hammersmith Hospital Imperial College
NHS Trust (R13077; 12275; REC
12/WA/0196)
ID01,ID06,ID09,ID13, ID17,ID18
Chemicals, Peptides, and Recombinant Proteins
Recombinant human thrombopoietin PeproTech Cat#300-18
Recombinant human stem cell Factor PeproTech Cat#300-07
Recombinant human erythropoietin R&D Systems Cat#287-TC-500
Recombinant human IL3 PeproTech Cat#200-34
Recombinant human IL6 PeproTech Cat#200-06
Recombinant human GMCSF PeproTech Cat#300-03
Recombinant human G-CSF PeproTech Cat#300-23
May Grunewald solution Sigma-Aldrich Inc. (Merck KGaA) Cat#63590
Giemsa stain Sigma-Aldrich Inc. (Merck KGaA) Cat#48900
Maxpar PBS Buffer Fluidigm Cat#201058
Maxpar Cell-ID Cisplatin Viability Stain Fluidigm Cat#201064
Maxpar Cell Staining Buffer (CSB) Fluidigm Cat#201068
Maxpar Nuclear Antigen Staining Buffer Fluidigm Cat#201063
(Continued on next page)
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Continued
REAGENT or RESOURCE SOURCE IDENTIFIER
Barcode Perm Buffer Fluidigm Cat#201057
Cell-ID 20-Plex Pd Barcoding Kit
(Palladium Barcodes)
Fluidigm Cat#201060
Nuclear Antigen Staining Perm Buffer
(NP Buffer)
Fluidigm Cat#201063
Cell-ID Intercalator-Ir Fluidigm Cat#201192A
Maxpar Fix and Perm Buffer Fluidigm Cat#201067
EQ Four Element Calibration Beads Fluidigm Cat#201078
Cell Conditioning 2 (CC2) antigen retrieval F. Hoffmann-La Roche Ltd. Cat#950-123
Ventana DISCOVERY antibody diluent F. Hoffmann-La Roche Ltd. Cat#760-108
Critical Commercial Assays
Stemspan SFEM STEMCELL Technologies Cat#09650
MethoCult H4435 Enriched STEMCELL Technologies Cat#04435
Chromium Single Cell 30 GEM Library
and Gel Bead Kit v2
10x Genomics, Inc. Cat#1000075
Chromium Single Cell 30 GEM Library
and Gel Bead Kit v3
10x Genomics, Inc. Cat#1000092
Chromium Chip B Single Cell Kit 10x Genomics, Inc. Cat#1000074
MiSeq Reagent Kit V2 Illumina Cat#102-2001
Nextera XT DNA Sample Preparation Kit Illumina Cat#FC-131-1024
EasySep Human CD34 Positive Selection Kit STEMCELL Technologies Cat#18096
Maxpar X8 Antibody Labeling Kit Fluidigm Cat#PRD002
pcDNATM 3.4 TOPOTM TA Cloning Kit Thermo Fisher Scientific A14697
ExpiCHOTM Expression System Kit Thermo Fisher Scientific A29133
rProtein A Sepharose 4 Fast Flow
Affinity Media
GE HealthCare Life Sciences 17-1279-03
CypHer5E NHS Ester GE Healthcare Life Sciences,
supplied by VWR
VWF PA15401
Monoclonal Anti-DNP antibody, human
IgG1 (N297A) isotype control
ACRO Biosystems DNP-MB273
Microscope slides with 10 flat wells Hendley-Essex PH056
Dynasore Sigma-Aldrich Inc. (Merck KGaA) D7693
Pitstop2 Sigma-Aldrich Inc. (Merck KGaA) SML1169
Deposited Data
10X single cell-seq data in this manuscript This manuscript GSE144568
TARGET-Seq data Rodriguez-Meira et al., 2019 GSE122198
Experimental Models: Cell Lines
HEL(human erythroleukemia) ATCC RRID:CVCL_8059
JURKAT ATCC RRID:CVCL_0367
K562 ATCC RRID:CVCL_0004
HEK ATCC RRID: CVCL_0045
HL-60 ATCC RRID:CVCL_0002
MARIMO ATCC RRID: CVCL_6992
SET-2 Laboratory of Prof. Jacqueline
Boultwood
RRID:CVCL_2187
Oligonucleotides
JAK2_WT_VIC sequence VIC TCTCCAC
AGACACATAC MGBNFQ
Moliterno et al., 2006 Applied Biosystems Custom Oligo
Synthesis service
JAK2V617F_MUT_FAM sequence 6FAM
TCCACAGAAACATAC MGBNFQ
Moliterno et al., 2006 Applied Biosystems Custom Oligo
Synthesis service
(Continued on next page)
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LEAD CONTACT AND MATERIALS AVAILABILITY
Further information and requests for resources or materials will be fulfilled by bethan.psaila@ndcls.ox.ac.uk or adam.mead@imm.ox.
ac.uk
Cell lines
HEL, JURKAT, K562, HEK, HL60 and MARIMO cells were obtained from the American Type Culture Collection (ATCC). SET-2 cells
were kindly provided byDr. Jacqueline Boultwood andDr. Andrea Pellagatti (Radcliffe Department ofMedicine, University of Oxford).
All cells were maintained in culture in RPMI-1630 supplemented with 10% fetal calf serum (FCS) and 1% penicillin-streptomycin.
SET-2 cells were supplemented with 20% FCS.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
A summary of demographic and clinical details of myelofibrosis patients and normal donors used for analysis can be found in Tables
S1 and S2.
METHOD DETAILS
Banking and processing of human samples
Patientsandnormaldonorsprovidedwritten informedconsent inaccordancewith theDeclarationofHelsinki for samplecollection, tissue
banking and use in research under either the INForMedStudy, University of Oxford (IRAS: 199833; REC 16/LO/1376) or Imperial College
London (approval reference: R13077; HTA license 12275; REC 12/WA/0196). Cryopreserved peripheral bloodmononuclear cells stored
in FCS with 10% DMSO were thawed and processed by warming briefly at 37C, gradual dilution into RPMI-1630 supplemented with
10% FCS and 0.1mg/mL DNase I, centrifuged at 500G for 5 minutes and washed in FACS buffer (PBS + 2mM EDTA + 10% FCS).
Continued
REAGENT or RESOURCE SOURCE IDENTIFIER
JAK2_FOR AAG CTT TCT CAC AAG
CAT TTG GTT T
Moliterno et al., 2006 Eurofins Genomics Custom oligos
JAK2_REV CCA AAT TTT ACA AAC
TCC TGA ACC AGA A
Moliterno et al., 2006 Eurofins Genomics Custom oligos
Software and Algorithms
CyTOF Software Fluidigm https://www.fluidigm.com/software
Cytobank Kotecha et al., 2010 https://mrc.cytobank.org
Flowjo version (10.5.3) FlowJo https://www.flowjo.com
GraphPad Prism GraphPad Software Inc. https://www.graphpad.com
R (v3.6.1) Team R C, 2013 https://cran.r-project.org/bin/macosx/
Cell Ranger v3.0.1 10x Genomics, Inc. https://github.com/10XGenomics/cellranger
RStudio (v1.1.463) Team R S, 2015 https://rstudio.com/products/rstudio/download/
Scanpy (v1.4.5) Wolf et al., 2018 https://icb-scanpy.readthedocs-hosted.com/
en/stable/
TARGET-Seq analysis pipeline Rodriguez-Meira et al., 2019 https://github.com/albarmeira/TARGET-seq
Other
AUCell_1.6.1 Aibar et al., 2017 https://www.bioconductor.org/packages/
release/bioc/vignettes/AUCell/inst/doc/
AUCell.html
sva_3.32.1 Johnson et al., 2007 https://bioconductor.org/packages/release/
bioc/vignettes/sva/inst/doc/sva.pdf
uwot_0.1.5 McInnes et al., 2018 https://cran.r-project.org/web/packages/
uwot/index.html
igraph_1.2.4.2 Csardi and Nepusz, 2005 https://cran.r-project.org/web/packages/
igraph/igraph.pdf
RANN_2.6.1 https://cran.r-project.org/web/
packages/RANN/index.html
https://github.com/jefferislab/RANN
fa2 Jacomy et al., 2014 https://pypi.org/project/fa2/
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Fluorescent activated cell sorting (FACS) staining, analysis and cell isolation
FACS-sorting was performed using a Becton Dickinson Aria III or Fusion 2 and cells isolated into 1.5ml Eppendorf tubes or 96-well
plates depending on the experiment. Single color stained controls and fluorescence minus one (FMO) controls were used for all ex-
periments. HSPCs were stained with the following antibody cocktail (see Key Resources Table) for 20 minutes at 4C and passed
through a 70 mm mesh cell strainer if necessary prior to sorting: CD34-APC-efluor780; Linege-BV510; CD38-PE-TxRed;
CD123-PeCy7; CD45RA-PE; CD71-AF700; CD41-APC; CD90-BV421. The following antibody cocktail was used to analyze cell dif-
ferentiation: CD34-APC-efluor780, CD71-AF700, CD36-FITC, CD41 PeCy7, CD42 PE, CD11b-APC, CD14-APC. 7AAD was used for
live/dead cell exclusion. For G6B immunostaining, cells were stained with anti-human G6B (17-4) for 30 minutes at 4C (1:100),
washed and stained with goat anti-mouse Alexa Fluor 488 secondary IgG antibody (2:200 ThermoFisher Cat#A10680) for 20 minutes
in the fridge and washed prior to staining with fluorescence-conjugated commercial antibodies.
In vitro liquid culture differentiation assays
Cells were isolated by FACS into 1.5 mL eppendorfs, centrifuged at 500G for 5 minutes, resuspended in 100ul culture medium and
plated in flat-bottom 96-well plates (Corning). Media used was Stemspan SFEM (StemCell Technologies #09650) + 1% Pen/Strep
supplemented with the following cytokines (see also Key Resources)
Cells were analyzed by FACS on days 6 and 14 (50 mL removed from wells for analysis and replaced with fresh media).
Cytospins and MGG
Cells were FACS-isolated into 1.5ml Eppendorf tubes, centrifuged and resuspended into 200 mL PBS and cytospun at 500RPM for
5minutes onto Superfrost glass slides. MayGrunewald Giemsa stain was prepared as permanufacturers protocol, filtered and slides
stained in May-Grunewald for 7 minutes followed by 20 minutes in Giemsa then washed in distilled water, air-dried and coverslip
applied.
Methocult assay
Single cells were FACS-isolated into flat bottomed 96-well plates containing 100 mL ofMethoCultTMH4435 Enriched (StemCell Tech-
nologies Cat#04435). Colonies were visually inspected and classified 11-14 days after plating. Lineage assignment was made by
morphological assessment with verification of ambiguous colonies by plucking and FACS analysis.
High-throughput single-cell RNA-sequencing (10x Chromium)
Cells were thawed, stained with FACS antibodies and sorted on a BD Aria III or Fusion 2 as described above and as per recommen-
dations in the 10x Genomics Single Cell Protocols – Cell Preparation Guide. 15,000 CD34+ lineage negative cells were sorted into
2 mL PBS/0.05% BSA (non-acetylated) and then the cell number/volume adjusted to the target for loading onto the 10x Chromium
Controller. Samples were processed according to the 10x protocol using the Chromium Single Cell 30 library and Gel Bead Kits v2
(batch 1) or v3 (batch 2) (10x Genomics). Cells and reagents were prepared and loaded onto the chip and into the Chromium
Controller for droplet generation. RT was conducted in the droplets and cDNA recovered through demulsification and bead purifi-
cation. Pre-amplified cDNA was used for library preparation, multiplexed and sequenced on a HiSeq 2500 (batch 1) or a Novaseq
Lineage culture Cytokine Concentration
Megakaryocyte single lineage rhTPO 100ng/ml
rhSCF 50ng/ml
Erythroid single lineage EPO 1U/ml increasing to 3U/ml from day 6
IL3 10ng/ml
IL6 20ng/ml
SCF 100ng/ml
Myeloid single lineage SCF 100ng/ml
G-CSF 20ng/ml
GM-CSF 20ng/ml
Bi-potent Ery-MK EPO 1U/ml
TPO 100ng/ml
SCF 100ng/ml
IL3 10ng/ml
IL6 20ng/ml
ll
Article
e4 Molecular Cell 78, 477–492.e1–e8, May 7, 2020
S4 (batch 2) aiming to obtain > 50,000 reads per cell. For some samples, a preliminary, low-depth run was done on a MiSeq using
MiSeq Nano Reagent Kit V2 (Illumina Cat#102-2001) to estimate the number of cells and total sequencing required.
TARGET-seq analysis
The count matrix for 8 myelofibrosis patients and two healthy donors profiled using 30TARGET-seq were downloaded from
GSE122198, normalized by library size and log2-transformed as previously described (Rodriguez-Meira et al., 2019). Cells were clas-
sified into WT-normal (cells from normal donors), WT-patient (non mutant cells present in patient samples) and mutant (cells from
patient samples carrying mutations in the genes targeted).
RNA sequencing of ‘mini-bulk’ HSPC populations
100 cells from each population were isolated by FACS into 4 mL of lysis buffer containing oligo-dT primer and dNTPmix in 0.2mLPCR
tubes. Cell lysis, RT and PCR preamplification and purification was performed using the Smart-Seq 2 protocol as previously pub-
lished (Picelli et al., 2014). Libraries were pooled and tagmentation performed using the Illumina Nextera XT DNA sample preparation
kit (Illumina Cat #FC-131-1024), libraries pooled and sequenced on a HiSeq 2000.
Antibody labeling with metal conjugates and mass cytometry (CyTOF)
Antibodies were purchased pre-conjugated when commercially available. Non-available antibodies were conjugated to lanthanide
metals usingMaxpar X8 antibody labeling kit according to themanufacturer protocol (version 10). The antibody cocktail used is listed
in Table S7. For barcoding and staining, cells were washed with Maxpar PBS buffer (Fluidigm #201058) and stained with 0.5 mM
Cell-ID Cisplatin Viability Stain (Fluidigm #201064) in 200 mL Maxpar PBS for 5 mintutes at room temperature for dead cell exclusion.
The reaction was quenched with Maxpar Cell Staining Buffer (CSB, Fluidigm #201063) and cells fixed, permeabilized and barcoded
using the Cell-ID 20-Plex Pd Barcoding Kit (Fluidigm #201060) as per the manufacturers user guide. Barcoded cells were washed,
combined and stainedwith the antibody cocktail as per Table S7 for 30minutes at room temperature. Cells werewashedwithMaxpar
Cell Staining Buffer (Fluidigm #201068), fixed in 1.6% formaldehyde, washed and resuspended in Fix&Perm Buffer (Fluidigm
Cat#201067) with Cell-ID intercalator-Ir (Fluidigm #201103B) and incubated overnight at 4C. The following day, cells were washed
and analyzed on a Helios (Fluidigm). The mass cytometer was tuned and QC was run prior to acquiring samples according to the
manufacturers’ recommendations.
G6B Immunohistochemistry
Sections of formalin fixed and paraffin embedded (FFPE) bone marrow trephine biopsies were processed as follows: paraffin was
removed, then antigen retrieval was performed using citrate (Roche Cell Conditioning 2 Cat#950-123) pre-treatment for 30 minutes.
Sections were washed and incubated with G6B antibody diluted 1:100 in Ventana’s DISCOVERY antibody diluent (Roche Cat#760-
108) for 60minutes at room temperature. Secondary detection was performed using UltraMapDAB anti-MsHRPdetection kit (Roche
#760-152) for 16 minutes and slides counterstained with hematoxylin (Roche #760-2021) for 4 minutes and Bluing reagent (Roche
#760-2037) for 4 minutes.
Sorting G6B+ and G6B- HSPCs for JAK2V617F qRT-PCR
For each experiment, MNCs from myelofibrosis patients and healthy donor controls were thawed and combined 1:1 in FACS buffer
prior to antibody staining as described above. 50 G6B+ and G6B- cells were sorted into each well of a 96-well PCR plate (10 repli-
cates per population for each experiment), containing CellsDirect One-Step qRT-PCR kit 2X Reaction Buffer and SuperScript III RT/
Platinum Taq Mix (Thermo Fisher Cat#11753100), Ambion SUPERase-In RNase inhibitor (Thermo Fisher Cat#AM2694), TE buffer,
JAK2 forward and reverse primers and wild-type and JAK2V617F-specific probe mix (see Key Resources Table). RT and PCR
were performed as per manufacturer’s recommendations with 18 pre-amplification cycles and then diluted 5x in TE buffer. Taqman
RT-PCR was performed in a 20 mL reaction volume using 4 mL of the diluted cDNA, Taqman Fast Advance Mastermix (Thermo
Fisher Cat#4444556) and the primers/probes as detailed in the Key Resources Table. Custom Taqman assays were designed
(see Key Resources Table) as previously described (Moliterno et al., 2006) using RT-PCR primers flanking the mutant region plus
two Taqman PCR probes specific for the normal or mutant sequence. An Applied Biosystems 7500 Fast Real-Type PCR system
was used with the default PCR conditions, with each replicate run in duplicate. Intra-assay replicates varying more than 5% were
excluded.
CD34 x G6B bispecific antibody generation
The CD34 x G6B bispecific antibody contains a human IgG1 Fc and was produced using ‘knobs-into-holes’ technology, which in-
volves generating a single amino acid substitution in opposite CH3 domains (Ridgway et al., 1996). Each sequence was inserted into
the pcDNA 3.4 expression vector (Thermo Fisher). Following preparation of plasmid DNA, each chain was co-transfected into Chi-
nese Hamster Ovarian cells at a 200 mL scale using the ExpiCHO expression system (Thermo Fisher). The Max Titer protocol was
followed. Cells were incubated in a 37C incubator with a humidified atmosphere of 8%CO2 in air on an orbital shaker. On the day after
transfection, ExpiFectamine CHO Enhancer and ExpiCHO Feed was added to the flask at the appropriate volume and the flask was
transferred to a 32C incubator with a humidified atmosphere of 5% CO2 in air on an orbital shaker. On Day 5 post-transfection, the
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second volume of ExpiCHOFeedwas added to the flask. OnDay 14, the cells were harvested by centrifuging at 18,000 x g for 30min.
The protein was purified from the supernatant using protein A affinity resin (GE HealthCare Life Sciences). Bound protein was eluted
with 20 mM Citrate at pH 2.9 and then immediately neutralized with 10% 1 M Tris. The protein was then further purified using size
exclusion chromatography (SEC), and characterized by SDS-PAGE gel and analytical scale SEC.
Antibody internalization experiments
The CD34 x G6B bispecific and a non-targeting isotype control (DNP-MB273, Acrobiosystems) were conjugated to CypHer5E (GE
Healthcare Life Sciences), a red-excitable, pH-sensitive cyanine dye detected in the APC or Ax647 channel that maximally fluoresces
at an acidic pH (i.e., after movement from a receptor on the cell surface to acidic endosomes upon internalization). HEL and SET-2
cells were re-suspended in serum-free, no phenol red RPMI and incubated with DMSO or inhibitors for 30 minutes at 37C, 5%CO2
prior to the addition of either the CD34 x G6B bispecific or isotype control (5 mg/ml), followed by a further incubation for 30 minutes at
37C, 5%CO2. For flow cytometry, cells were then washed twice with PBS and re-suspended in PBS for flow analysis on a Beckman
Flow CytoFLEX cytometer. For live cell imaging, cells were plated onto slides with flat wells (Hendley-Essex) and imaged on a Zeiss
inverted confocal LSM870 with an apochromatic 40X oil immersion objective lens. Two inhibitors were used - Dynasore, a GTPase
inhibitor of dynamin (Sigma) (Macia et al., 2006) at 100 mM and Pitstop 2 (Sigma) (von Kleist et al., 2011) at 30 mM concentration, that
inhibits the clathrin terminal domain as well as clathrin-independent endocytosis.
10x Genomics single-cell RNA sequencing data pre-processing and integration
Sequencing data in the binary base call (BCL) format were demultiplexed. Unique molecular identifier (UMI) counts were obtained by
aligning FASTQ files to the human reference genome (GRCh38 3.0.0) using Cell Ranger software (version 3.0.1) from 10x Genomics.
The CellRanger ‘‘count’’ standard pipeline was used to obtain the expression matrix for each individual library for each donor. Cells
meeting the following QC parameters (detailed in Table S3) were included in analyses: UMI counts > 1,000 and%maximum UMIs);
number of detected genes > 500 and % maximum number of detected genes); the percentage of mitochondrial gene expression <
15% per cell. Genes expressed in at least 10 cells were included. Following application of these filters, 122,154 cells passed quality
control (83,753 cells from myelofibrosis patients and 38,401 cells from healthy donors, see Table S3). We scaled UMI counts by
normalizing each library size to 10000. The normalized expression values were then log transformed (Ritchie et al., 2015).
Dimensionality reduction, removal of individual donor effect and cell clustering
Sparse expression matrices of cells obtaining from the CellRanger output for individual donor were combined. Highly variable genes
were identified by fitting mean expression values and the squared coefficient of variation (CV2) calculated with a gamma generalized
linear model using the ‘‘glmgam.fit’’ function in the statmod package in R as described previously (Brennecke et al., 2013). Using a
mean expression value of > 0.05 and the dispersion score of > 0.05, 800 genes were identified as highly variable genes. 12 ribosomal,
mitochondrial and heat shock protein genes were removed (Kampinga et al., 2009; Nakao et al., 2004), resulting in 788 highly variable
genes being used for down-stream analysis. Donor effect was regressed out using Combat from the sva package (Johnson et al.,
2007) by regressing out on the donor IDs. Following this, there was no clear batch effect in the dataset (Figure S1C). Principal Compo-
nent Analysis (PCA) was then performed on normalized expression values on the first 50 principal components (PCs). An elbow plot
was inspected to determine the appropriate number of top PCs capturing themost of variances. Using this approach, we selected the
first 20 PCs for further analyses. Uniform Manifold Approximation and Projection (UMAP) analysis was performed using the ‘‘uwot’’
function on the embedded matrix derived from the first 20 PCs and 30 neighbors using cosine as the metric parameter. Cells were
clustered using the k-nearest neighbor (KNN) approach, using Euclidean metric as the input parameter. The weighted graph was
createdwith theweight values calculated from the normalized shared number of the nearest neighbors. The function ‘cluster_louvain’
from the igraph package (Csardi and Nepusz, 2005) was then applied to identify clusters based on the weighted graph. Identified
clusters were superimposed on the two-dimensional UMAP.We identified a distinct cluster (n = 1,958 cells) expressing a gene signa-
ture corresponding to plasmacytoid dendritic cells (pDC) (Figure S1D) and we removed this cluster from further analyses as they are
not hematopoietic stem/progenitor cells but contaminating mature cells that fall into the CD34+Lin– FACS gate. After removing the
pDC cluster, 120,196 cells (82,255 frommyelofibrosis donors and 37,941 cells from healthy donors) from all 21 donors (myelofibrosis
patients + controls) were included in analyses. Highly variable genes were recalculated, and 817 were identified; 12 of which were
removed (heat-shock/mitochondrial/ribosomal genes), resulting in 805 highly variable genes being used for all downstream analyses.
Eighteen clusters were initially identified, differentially expressed genes inspected and clusters with similar profiles were merged.
This resulted in eight major clusters representing HSPC and lineage progenitor populations, as shown in Figures 2A and 2B.
Lineage signature gene sets
Lineage signature gene sets were collated by curating known canonical lineage markers selected from multiple recently published
hematopoiesis datasets (Buenrostro et al., 2018; Hua et al., 2019; Pellin et al., 2019; Popescu et al., 2019). Genes selectively ex-
pressed in hematopoietic lineage progenitors and uncommitted HSPCs were identified (see Table S5). Expression of each gene
was plotted individually on the UMAP plot and genes that were highly expressed and most specifically marked distinct lineage clus-
ters or uncommitted HSPCs in the HSPC UMAP were selected for inclusion in the ‘signature gene sets’ (see Figure S2). These gene
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sets were used to calculate a ‘lineage gene score’ for each cell, based on the average gene expression of each lineage gene set.
These scores were superimposed on the UMAP and FDG plots (Figures 2B and 3).
Marker gene identification and cell type annotation
Differentially expressed genes for each cluster were identified using the nonparametric Wilcoxon test on the log-transformed,
normalized UMIs to compare expression level. Fisher0s exact test was used to compare the cell frequency expressing each gene
as previously described (Giustacchini et al., 2017). P values generated from both tests were then combined using Fisher’s method
and were adjusted using the Benjamini-Hochberg (BH) correction. Genes expressed by each individual cluster were compared to all
other clusters and differential expression defined as an absolute log2 fold change of R 0.5 and adjusted P value of < 0.05, with the
fraction of expressing cell frequency of > 0.3. Differentially expressed genes were ranked usingP values and log2FC to select up to 50
genes per cluster (Tables S4 and S6). Clusters were identified by manual inspection of differentially expressed genes for canonical
marker genes of blood cell lineages. All heatmaps show scaled (z-score) expression values.
Down-sampling of myelofibrosis cells
To generate a dataset with equal numbers of myelofibrosis and control cells, myelofibrosis cells were ‘down-sampled’ to 37,941
cells. This number is equal to the maximum number of cells that passed QC in the healthy control. These cells were integrated
with all the cells from healthy donors, and analyses from normalization to clustering as described above were repeated. 722 highly
variable genes were detected and 12 ribosomal, mitochondrial and heat shock protein genes were removed, resulting in 710 highly
variable genes used for subsequent analyses. Seventeen clusters were identified initially, clusters expressing erythroid, megakaryo-
cyte, myeloid and lymphoid genes signatures were merged (Figure S1F). The percentage of cells in each of these lineage clusters
from each donor type was quantified (Figure 2D).
MkP identification and sub-clustering analysis
Using the samemethod as described above, cells from the two donor types (healthy donor controls and myelofibrosis patients) were
integrated separately. 847 and 680 highly variable genes were detected and 18 and 14 clusters for the MF and control respectively.
As shown in Figure S4A, clusters 8, 13, 14, 15, and 16 (n = 8134 cells) were identified as MkP clusters in the myelofibrosis UMAP and
clusters 13 and 14 (n = 141 cells) in the healthy donor UMAP. We used the AUCell package (Aibar et al., 2017) to calculate the AUCell
score for megakaryocyte signature genes for each individual cell within these clusters. Based on the score distribution, we selected
AUCell score > 0.4 (Figure S4A) to define MkP. This resulted in 4,134 and 139 MkP cells being identified from myelofibrosis and
healthy control donors respectively. To examine the heterogeneity amongmyelofibrosis MkP, normalization and clustering were per-
formed as described above. 20 PCs were used for analysis and 1195 highly variable genes were identified after removing 11 ribo-
somal, mitochondrial, and heatshock protein genes. Clustering analysis revealed 9 sub-clusters of myelofibrosis MkP (Figure 5D).
Individual donor analysis
After removing plasmacytoid dendritic cells for each individual, a standard pipeline described above was used. 20 PCs and 30 neigh-
bors were used for UMAP and clustering analyses. 20 PCs and 5 neighbors were used for the force-directed graph (FDG) analysis
(Figure S3).
Differentiation trajectory analysis
ForceAtlas2 software (Jacomy et al., 2014) was used to visualize differentiation trajectories over the force-directed graph layout. The
KNNweighted graphwas used as the input for the software, and analysis performedwith the following parameters: iterations = 1,000,
edgeWeightInfluence = 1, barnesHutTheta = 2, scalingRatio = 1, gravity = 0.05 and jitterTolerance = 1. The output layout was plotted
using ggplot2 and superimposed with normalized lineage signature gene scores (average expression values) for myeloid, erythroid,
lymphoid and megakaryocyte lineages (Table S5). Transparent factors for selected colors were calculated from normalized expres-
sion values across cell types. ggplot2 was used, adding the dynamic alpha parameter values to ‘‘geom_point’’ to control the trans-
parency of colors as shown in Figures 3A, 3B, and 3C.
To identify the differentiation paths, the PAGA function in the Scanpy toolkit was used (Wolf et al., 2018, 2019). Clusters were iden-
tified using canonical lineage maker genes as hematopoietic stem cell (HSC), hematopoietic stem/progenitor cell (HSPC1, HSPC2,
HSPC3), erythroid (Ery), megakaryocyte (Mega) and myeloid (Mye) (Figure 4A), with HSC clearly positioned at the root of the trajec-
tory. As shown in Figures 4A and 4B, the predominant path for megakaryocyte differentiation was HSC / HSPC2 / Mk.
Scanpy (version 1.4.5) was used for UMAP, FDG, and diffusion maps analyses (Figure S3D) to compare the results of our in-house
analysis pipeline with the existing analysis tool. The ‘sc.pp.combat’ function in scanpywas used to correct donor effect by regression
out donor IDs. The ‘sc.pp.highly_variable_genes’ function was used by setting ‘n_top_genes’ to the same number of genes used in
the in-house pipeline. 20 PCs and 30 neighbors were used to run UMAP, diffusionmap, and FDG functions. Megakaryocyte signature
genes (Table S5) were superimposed on the UMAP, diffusion map and FDG.
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Identifying patters of expression of transcription factor genes along megakaryocyte and erythroid trajectories in
myelofibrosis patients
To examine expression of 1,639 transcriptional factors (Lambert et al., 2018) along the megakaryocyte and erythroid differentiation
trajectories, the 82,255 myelofibrosis HSPCs were clustered by the Louvain community-detection method (resolution = 0.5). Seven
major clusters were identified and projected on the FDG layout using Scanpy. Differentially expressed genes for each cluster were
identified as described above. 16 transcription factor genes showing progressive changes, either increased or decreased expres-
sion, along the two trajectories were selected (Figures 4B and 4C).
The heatmap was generated by calculating the running average of the gene expression for cells along the path using the function
‘scanpy.pl.paga_path’ in Scanpy to investigate dynamic changes in gene expression. The n.avg parameter was set at 5000 for the
number of data points to include in the computation of the running average, to ensure a smooth transition.
GeneSet Enrichment Analysis
GSEA was performed using GSEA software (https://www.gsea-msigdb.org/gsea/index.jsp) with ‘Run GSEAPreranked’ and default
parameters. The HALLMARK gene set used for the analysis was downloaded from MSigDB (https://www.broadinstitute.org/gsea/
msigdb/collections.jsp). 9,313 expressed genes were used for the analysis. Genes were pre-ranked in order of their differential
expression between myelofibrosis and healthy donor megakaryocyte progenitors. The Pathways with FDR q-value < 0.25 were
selected showing in Figure 5B.
Integration of 10x Genomics and TARGET-seq datasets
37,941 cells (the down-sampled dataset) from 15myelofibrosis patients processed using theChromiumplatform (10xGenomics) and
2,071 cells from 8 myelofibrosis patients (obtained from Rodriguez-Meira et al., 2019; GSE122198) were projected into a shared
embedding with Harmony (Korsunsky et al., 2019), using the top 20 PCA dimensions. The effect of the platform (10X Genomics/
TARGET-seq) and donor were simultaneously accounted for and introduced as covariates. Then, dimensionality reduction and force
directed graph analysis were performed as described above (Dimensionality reduction, removal of individual donor effect and cell
clustering). To quantify the proportion of mutant and wild-type cells in each lineage progenitor cluster, clusters were identified by
inspection of differentially expressed genes and super-imposition of the lineage gene set scores on the UMAP and FDG graphs
as described above, and mutant and wild-type cells enumerated for myeloid, eythoid and megakaryocyte progenitor clusters. Pro-
portions of wild-type and mutant cells for each of cluster pair were compared using a Chi-square test (p value) with Yates’ continuity
correction.
QUANTIFICATION AND STATISTICAL ANALYSIS
Flow cytometry and CyTOF data analysis
Flow cytometry data was analyzed using FlowJo software (v10.5.3). Summary charts and associated statistical analyses were per-
formed using GraphPad Prism (v8.1.0). Helios CyTOF Software (v6.7) was used for processing of FCS 3.0 files, normalization to EQ
Beads, concatenation of multiple files and debarcoding. Data was then analyzed and histograms and viSNE plots generated using
CytoBank.org.
Statistical tests used, numbers of replicates and definitions of statistical significance are described in the relevant figure legends.
All bar charts show mean ± standard error of the mean and were generated using GraphPad Prism (v.8.1.0).
To compare the proportions of wild-type versus mutant cells in lineage progenitor clusters (Figure S6A), Fisher’s exact test was
used. To compare the expression of key genes in different sub-clones within the same patients (Figures 6B, 6C, and S6B), Fisher’s
test was used to compare the expression frequencies between the groups and Wilcoxon rank sum test to compare the expression
levels. P values were combined using Fisher’s method, and the combined p value for each pairwise comparison are reported in
Figure S6.
DATA AND CODE AVAILABILITY
10x Genomics single cell RNA-sequencing data has been submitted to GEO database (Accession Number GEO: GSE144568).
TARGET-seq single cell RNA-sequencing data is available at Accession Number GEO: GSE122198. The Shiny application for visu-
alization of the data from patients and healthy donors in this study is available at https://github.com/supatt-lab/SingCellaR-
myelofibrosis. R scripts used for the analysis are available upon request.
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